Insulin allergy manifesting soon after COVID‐19 vaccination (BNT162b2)

Insulin allergy manifesting soon after COVID‐19 vaccination (BNT162b2)

Bibliographic Details
Main Authors:	Hiroshi Komamura, Yohei Kawana, Junta Imai, Hideki Katagiri
Format:	Article
Language:	English
Published:	Wiley 2023-03-01
Series:	Journal of Diabetes Investigation
Online Access:	https://doi.org/10.1111/jdi.13969

Similar Items

Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents
by: Suyanee Mansanguan, et al.
Published: (2022-08-01)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
by: Rieke Reiter, et al.
Published: (2022-05-01)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
by: Xin Rong Lim, et al.
Published: (2021-08-01)

Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2
by: Stilla Bauernfeind, et al.
Published: (2021-09-01)

Antibody responses after BNT162b2 vaccination in Japanese geriatric intermediate care facilities
by: Asae Suita, et al.
Published: (2023-12-01)

Allergy to PEG (polyethylene glycol) – sensitivity of basophil activation test with COVID-19 mRNA-vaccine BNT162B2
by: Bernadette Eberlein, et al.
Published: (2024-12-01)

Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
by: Ryoichi Miyazaki, et al.
Published: (2023-02-01)

Spontaneous pneumomediastinum after BNT162b2 COVID-19 vaccination in adolescents
by: Chi-Yan Lam, et al.
Published: (2023-07-01)

Immune-Mediated Thrombotic Thrombocytopenic Purpura after BNT162b2 Vaccine
by: Tekin Guney, et al.
Published: (2022-02-01)

Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru.
by: Natalia Vargas-Herrera, et al.
Published: (2022-01-01)

Keratoplasty rejection after messenger RNA vaccine (BNT162b2) for COVID-19
by: Maria Eduarda Andrade e Andrade, et al.
Published: (2022-01-01)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
by: Geon Young Ko, et al.
Published: (2023-10-01)

Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
by: Simone Barocci, et al.
Published: (2022-03-01)

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
by: Hazal Cansu Çulpan, et al.
Published: (2023-12-01)

BNT162b2 COVID-19 Vaccination and Its Effect on Blood Pressure
by: Toh Leong Tan, et al.
Published: (2022-12-01)

Extended interval BNT162b2 vaccination enhances peak antibody generation
by: Helen Parry, et al.
Published: (2022-01-01)

Neutralizing antibody titers to Omicron six months after vaccination with BNT162b2 in Colombia
by: María I. Zapata-Cardona, et al.
Published: (2022-12-01)

Blood Antibody Titers and Adverse Reactions after BNT162b2 mRNA Vaccination
by: Jolanta Kiewisz, et al.
Published: (2022-04-01)

Serum levels of prostate specific antigen (PSA) after primary vaccination with BNT162b2
by: De Nitto Simone, et al.
Published: (2023-08-01)

Durable immune responses after BNT162b2 vaccination in home-dwelling old adults
by: Lena Hansen, et al.
Published: (2023-04-01)

Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
by: Louise Murdoch, et al.
Published: (2023-09-01)

Antibody response and seroprevalence in healthcare workers after the BNT162b2 vaccination in a University Hospital at Tokyo
by: Gene Igawa, et al.
Published: (2022-05-01)

Pulmonary Embolism after Vaccination with the COVID-19 Vaccine (Pfizer, BNT162b2): A Case Report
by: Eun-Ju Kim, et al.
Published: (2023-06-01)

Cellular and Humoral Responses in Dialysis Patients after Vaccination with the BNT162b2 or mRNA-1273 Vaccines
by: Ilias Mavrovouniotis, et al.
Published: (2023-02-01)

The evaluation of factors affecting antibody response after administration of the BNT162b2 vaccine: a prospective study in Japan
by: Toshiya Mitsunaga, et al.
Published: (2021-10-01)

Type 1 Diabetes Mellitus Associated with Nivolumab after Second SARS-CoV-2 Vaccination, Japan
by: Toshihiro Sato, et al.
Published: (2022-07-01)

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
by: Payne, RP, et al.
Published: (2021)

Cost-effectiveness analysis of COVID-19 booster vaccination with BNT162b2 in Japan
by: Mitsuhiro Nagano, et al.
Published: (2024-12-01)

P1584: CELLULAR IMMUNE RESPONSE TO THE BNT162B2 VACCINE IN LYMPHOMA PATIENTS
by: R. Gurion, et al.
Published: (2022-06-01)

Hemophagocytic Lymphohistiocytosis Following BNT162b2 mRNA COVID-19 Vaccination
by: Ting-Yu Lin, et al.
Published: (2022-04-01)

Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome
by: Diletta Valentini, et al.
Published: (2022-01-01)

Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers
by: Giovanna Cocomazzi, et al.
Published: (2021-08-01)

Natural killer cells and BNT162b2 mRNA vaccine reactogenicity and durability
by: Elizabeth K. Graydon, et al.
Published: (2023-08-01)

The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation
by: Marika Watanabe, et al.
Published: (2022-01-01)

Lymphadenopathy after <i>BNT162b2</i> Covid-19 Vaccine: Preliminary Ultrasound Findings
by: Vincenza Granata, et al.
Published: (2021-03-01)

Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2
by: Julien Favresse, et al.
Published: (2021-07-01)

Specific immune responses after BNT162b2 mRNA vaccination and COVID-19 infection
by: Simona Arientová, et al.
Published: (2023-10-01)

Epigenomic landscape exhibits interferon signaling suppression in the patient of myocarditis after BNT162b2 vaccination
by: Hyeonhui Kim, et al.
Published: (2023-06-01)

Effect of vaccine dosing intervals on Omicron surrogate neutralization after three doses of BNT162b2
by: Martin A. Prusinkiewicz, et al.
Published: (2023-06-01)

The Persistence of Antibodies in ESRD Patients 12 Months after the BNT162b2 Vaccine Booster Dose.
by: Ummu Afeera, Zainulabid, et al.
Published: (2024)